J. Smolen and other European rheumatologists published
a paper in the Annals of Rheumatic Diseases on proposing a new nomenclature of
disease-modifying antirheumatic drugs.
Just now we distinguish sDMARDs, synthetic or chemical
DMARDs (also called traditional or conventional DMARDs) and biological DMARDs.
The
authors propose:
- boDMARDs for biologic original
DMARDs (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept,
golimumab, infliximab, rituximab or tocilizumab, and also emerging ones like
clazakizumab, ixekizumab, sarilumab, secukinumab or sirukumab)
- bsDMARDs for biosimilar DMARDs (in
principle the above mentioned ones, more particularly for the time being etanercept,
infliximab, and rituximab)
- tsDMARDs for targeted DMARDs
(small molecules, protein kinase inhibitors), die authors specify “those
[DMARDs] that were specifically developed to target a particular molecular
structure (such as tofacitinib, fostamatinib, baricitinib or apremilast, or
agents not focused primarily on rheumatic diseases, such as imatinib or
ibrutinib)”
- csDMARDs for traditional DMARDs (methotrexate, sulfasalazine, leflunomide,
hydroxychloroquine, gold salts, azathioprin, and others)
Let’s see where the
discussion leads us! I would be happy with this more stringent nomenclature.
Smolen JS, van der Heijde D, Machold
KP, Aletaha D, Landewé R. : Proposal for a new
nomenclature of disease-modifying antirheumatic drugs.
Ann Rheum Dis.
2014 Jan 1;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317. Epub 2013 Sep 26.
No comments:
Post a Comment